Wall Street Zen Upgrades Tvardi Therapeutics (NASDAQ:TVRD) to Hold

Tvardi Therapeutics (NASDAQ:TVRD) was upgraded by research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a report released on Saturday.

Other analysts also recently issued research reports about the stock. Raymond James Financial downgraded shares of Tvardi Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Tuesday, October 14th. Barclays set a $5.00 price target on shares of Tvardi Therapeutics and gave the company an “equal weight” rating in a report on Monday, October 13th. BTIG Research cut their price objective on shares of Tvardi Therapeutics from $55.00 to $15.00 and set a “buy” rating on the stock in a report on Monday, October 13th. Piper Sandler downgraded Tvardi Therapeutics from an “overweight” rating to a “neutral” rating in a research note on Monday, October 13th. Finally, Weiss Ratings reaffirmed a “sell (e)” rating on shares of Tvardi Therapeutics in a research report on Monday, December 29th. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Tvardi Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $55.50.

Tvardi Therapeutics Price Performance

Shares of TVRD opened at $3.72 on Friday. Tvardi Therapeutics has a 12 month low of $3.50 and a 12 month high of $43.65. The stock’s 50-day moving average is $4.20 and its two-hundred day moving average is $15.37. The stock has a market cap of $34.89 million, a PE ratio of -0.39 and a beta of 0.14.

Tvardi Therapeutics (NASDAQ:TVRD) last posted its earnings results on Thursday, November 13th. The company reported ($0.59) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.83) by $0.24.

Institutional Investors Weigh In On Tvardi Therapeutics

A number of institutional investors have recently modified their holdings of TVRD. JPMorgan Chase & Co. acquired a new position in Tvardi Therapeutics in the second quarter worth about $39,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new position in Tvardi Therapeutics during the 2nd quarter worth approximately $43,000. Headlands Technologies LLC bought a new position in Tvardi Therapeutics during the 2nd quarter worth approximately $80,000. New York State Common Retirement Fund acquired a new position in shares of Tvardi Therapeutics in the 2nd quarter worth approximately $92,000. Finally, Squarepoint Ops LLC bought a new stake in shares of Tvardi Therapeutics in the 3rd quarter valued at approximately $318,000. Institutional investors and hedge funds own 44.66% of the company’s stock.

About Tvardi Therapeutics

Cara Therapeutics, Inc, an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body’s peripheral nervous system and immune cells. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.